<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=1400074&amp;fmt=gif">

BIODESIX LUNG REFLEX


veristrat

The VeriStrat® blood-based immune profiling test provides a personalized view of each patient’s immune response to their lung cancer and helps inform physicians whether their patient has a more aggressive cancer.

Learn more about:

BIODESIX LUNG REFLEX TESTING

GENESTRAT TEST

What is the VeriStrat® test?

  • Blood-based proteomic test that provides a personalized view of each patient's disease state
  • Measures acute phase proteins and the acute phase response which indicates chronic inflammation and a more aggressive cancer
  • Impacts treatment strategy and facilitates disease state monitoring

 

Interpreting VeriStrat results

VeriStrat Good results indicate a disease state that is more likely to respond to standard of care treatment.

Download VeriStrat good report

VeriStrat Poor results indicate a chronic inflammatory disease state. These patients may benefit from an alternative treatment strategy2,6, including:

  • Clinical trials and novel combination therapies
  • Broad genomic profiling for rare mutations
  • Faster time to treatment, if active therapy is being considered
  • Palliative care

Download VeriStrat poor report

Data demonstrate VeriStrat Good patients survive twice as long compared with VeriStrat Poor patients, independent of treatment choice

Read the Veristrat peer-reviewed meta-analysis 

IMMUNOTHERAPY5

chart-immunotherapy

CHEMOTHERAPY7

chart-chemotherapy

TARGETED THERAPY2

chart-targeted-therapy

PLACEBO8

chart-placebo

Case Studies

Learn how some of the industry’s leading experts are using Biodesix Lung Reflex® testing in their practice.

Jonathan-Kurman

Jonathan Kurman, MD

Froedtert & the Medical College of Wisconsin

Michael-Pritchett

Michael Pritchett, DO, MPH

Chest Center of the Carolines at FirstHealth of the Carolinas

The Veristrat Proteomic Test is Covered by Medicare and Many Private Payers.

LEARN MORE ABOUT REIMBURSEMENT

Get in touch

Contact us

Data library

Discover more
  1. Fidler MJ, et al. BMC Cancer (2018) 18:310
  2. Buttigliero C, et al. The Oncologist. 2018 Aug 23.
  3. Grossi, F, et al. J Thorac Oncol. 2017; 12 (S1322 P3.02c-074).
  4. Grossi, F, et al. Br J Cancer. 2017 Jan 3; 116(1):36-43.
  5. Rich P, et. al 2019 (Multidisciplinary Thoracic Cancers Symposium poster).
  6. Mok T, et al. J Thorac Oncol. 2016 Oct; 11(10):1736-1744.
  7. Grossi, et al. Lung Cancer 117 (2018): 64–69.
  8. Carbone DP, et al. J Thorac Oncol. 2012;7(11):1653-1660.
  1. Reprinted from CHEST, 143 /5(Suppl), Detterbeck et al., Executive Summary Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines / Palliative and End-of-Life Care in Lung Cancer, Page No. 37S, Copyright (2013), with permission from Elsevier.
  2. Hagerty et al. Journal of clinical oncology 22, no.9 (2004): 1721-1730.
  3. Wright et al. Jama 300,no.14 (2008): 1665-1673.
  4. Sullivan et al. Journal of palliative medicine 10, no.4 (2007): 882-893.